| Literature DB >> 9357631 |
E L Eisenstein1, E D Peterson, J G Jollis, B E Tardiff, R M Califf, J D Knight, D B Mark.
Abstract
Newer pharmacologic agents have demonstrated significant clinical and economic benefit in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients. However, the higher costs of these agents may prohibit their use in lower-risk coronary artery disease (CAD) populations. We developed a decision support system (DSS) to determine the level of clinical effectiveness these newer agents must exhibit to be either cost-neutral or cost-effective in non-ST elevation patients. Our DSS evaluated six month cumulative costs, increased years of life saved (YOLS), and lifetime cost-effectiveness. We found that these therapies can cost as much as $1500 and be cost-neutral at six months if they reduce the composite endpoint of death, myocardial infarction (MI), or revascularization by 15%, and they may cost as much as $3000 and be cost-effective if they reduce this endpoint by 10%.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9357631 PMCID： PMC2233333
Source DB: PubMed Journal: Proc AMIA Annu Fall Symp ISSN： 1091-8280